SecBot SecBot
SECBOTREPLAY Home › Report › IOVA

IOVA · Iovance Biotherapeutics filed an S-3ASR shelf registration, enabling it…

IOVANCE BIOTHERAPEUTICS, INC. · S-3ASR filed Jun 18, 2026 at 16:31 ET

At the news

NEUTRALIMPACT 5/10

S-3ASR filed Jun 18, 2026 at 16:31 ET

Iovance Biotherapeutics filed an S-3ASR shelf registration, enabling it to offer and sell up to $89.7 million in common stock via an existing ATM agreement with Jefferies. The company has already drawn $260.3 million from the $350 million facility, and the remaining capacity is being refinanced under this new shelf. With a market cap of $1.8B, the potential dilution from the full $89.7M offering is roughly 5% of current shares outstanding, which is moderate. The 10-Q shows cash and investments of $425.7M in net tangible book value, but the company is pre-tax profitable and still burning cash on R&D and commercial launch costs, making this a capital-raising event to extend runway rather than a distress signal.

  • S-3ASR filed for an indeterminate amount of common stock, preferred stock, debt, warrants, units, and rights, with an immediate ATM component of $89.65M in common stock.
  • The ATM is a replenishment of a prior $350M facility: $260.35M already sold, leaving $89.65M remaining.
  • As of March 31, 2026, the company had 438.1M shares outstanding; full draw of $89.65M at $3.93/share would add ~22.8M shares, diluting by ~5.2%.
  • Net tangible book value was $425.7M ($0.97/share) at Q1 2026 end; pro forma after maximum ATM draw would be ~$513.3M ($1.11/share).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access